Literature DB >> 16429242

Plasmapheresis therapy in an elderly patient with rapidly progressive Henoch-Schönlein purpura with disseminated organ involvement.

J Rech1, F Fuchs, S Kallert, A J Hueber, C Requadt, B Manger, J R Kalden, K Amann, R Strauss, H Schulze-Koops.   

Abstract

Henoch-Schönlein purpura (HSP) frequently occurs in children below the age of 15 years and is rare with increasing age. Prognosis and therapy largely depend on the clinical presentation. The disease may be preceded by an upper respiratory tract infection, and drugs have also been implicated in the pathogenesis of the disease. Most children recover from the illness, whereas 40% of adults have persistent hematuria and 10% develop chronic renal failure. Recent studies strongly suggest that adults with HSP should be monitored for prolonged periods and treated aggressively. Here, we present a case of a patient with HSP who developed multiorgan failure requiring assistance in breathing and dialysis, and also sustained gastrointestinal bleeding despite aggressive immunosuppressive therapy. In analogy to published data in children with severe HSP, the patient was treated by plasma exchange in combination with low dose oral cyclophosphamide, while high dose steroids were reduced over time. The patient could be discharged 70 days after admission. One year after discharge, the patient is doing well without any signs of activity of HSP and completely unremarkable renal function. The maintenance daily dose of steroids is 7.5 mg.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16429242     DOI: 10.1007/s10067-005-0113-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  8 in total

Review 1.  Henoch Schonlein purpura in children and adults: is it one entity?

Authors:  Y Ilan; Y Naparstek
Journal:  Semin Arthritis Rheum       Date:  2002-12       Impact factor: 5.532

2.  Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactoid purpura.

Authors:  F Mollica; S Li Volti; R Garozzo; G Russo
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

3.  The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura.

Authors:  J A Mills; B A Michel; D A Bloch; L H Calabrese; G G Hunder; W P Arend; S M Edworthy; A S Fauci; R Y Leavitt; J T Lie
Journal:  Arthritis Rheum       Date:  1990-08

4.  Plasmapheresis as the sole therapy for rapidly progressive Henoch-Schönlein purpura nephritis in children.

Authors:  M Hattori; K Ito; T Konomoto; H Kawaguchi; T Yoshioka; M Khono
Journal:  Am J Kidney Dis       Date:  1999-03       Impact factor: 8.860

5.  Retrospective study of plasma exchange in patients with idiopathic rapidly progressive glomerulonephritis and vasculitis.

Authors:  A Gianviti; R S Trompeter; T M Barratt; M F Lythgoe; M J Dillon
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

6.  Plasmapheresis therapy for rapidly progressive Henoch-Schönlein nephritis.

Authors:  Yukihiko Kawasaki; Junzo Suzuki; Michihiko Murai; Ai Takahashi; Masato Isome; Ruriko Nozawa; Shigeo Suzuki; Hitoshi Suzuki
Journal:  Pediatr Nephrol       Date:  2004-06-09       Impact factor: 3.714

7.  Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis.

Authors:  P Niaudet; R Habib
Journal:  Pediatr Nephrol       Date:  1998-04       Impact factor: 3.714

8.  A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383].

Authors:  Adam M Huber; Jim King; Peter McLaine; Terry Klassen; Mary Pothos
Journal:  BMC Med       Date:  2004-04-02       Impact factor: 8.775

  8 in total
  6 in total

Review 1.  Gastrointestinal manifestations of Henoch-Schonlein Purpura.

Authors:  Ellen C Ebert
Journal:  Dig Dis Sci       Date:  2008-03-20       Impact factor: 3.199

2.  Henoch-Schönlein purpura complicated with severe gastrointestinal bleeding.

Authors:  Tomoyuki Yamazaki; Tetsu Akimoto; Yoshitaka Iwazu; Taro Sugase; Eri Takeshima; Akihiko Numata; Takanori Komada; Hiromichi Yoshizawa; Naoko Otani; Yoshiyuki Morishita; Osamu Saito; Fumi Takemoto; Shigeaki Muto; Eiji Kusano; Daisuke Nagata
Journal:  CEN Case Rep       Date:  2014-10-02

3.  The clinical implications of adult-onset henoch-schonelin purpura.

Authors:  Warit Jithpratuck; Yasmin Elshenawy; Hana Saleh; George Youngberg; David S Chi; Guha Krishnaswamy
Journal:  Clin Mol Allergy       Date:  2011-05-27

4.  Massive lower gastrointestinal haemorrhage, successfully treated with corticosteroids, as main symptom of Schönlein-Henoch purpura.

Authors:  F Alvarez-Caro; J A Concha-Torre; I García-Hernández; S Menéndez-Cuervo; M Los Arcos-Solas; J Santos-Juanes; E Ramos-Polo
Journal:  Rheumatol Int       Date:  2009-01-21       Impact factor: 2.631

5.  Successful treatment of Henoch-Schonlein purpura nephritis with plasma exchange in an adult male.

Authors:  Kunal Chaudhary; Ji-Young Shin; Georges Saab; Alan M Luger
Journal:  NDT Plus       Date:  2008-07-25

6.  Long-Term Therapeutic Plasma Exchange to Prevent End-Stage Kidney Disease in Adult Severe Resistant Henoch-Schonlein Purpura Nephritis.

Authors:  Patrick Hamilton; Olumide Ogundare; Ammar Raza; Arvind Ponnusamy; Julie Gorton; Hana Alachkar; Jamil Choudhury; Jonathan Barratt; Philip A Kalra
Journal:  Case Rep Nephrol       Date:  2015-11-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.